{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:19:49Z","timestamp":1790759989049,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum Genet"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00439-019-01976-z","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T08:36:12Z","timestamp":1549528572000},"page":"483-489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Gene therapies in canine models for Duchenne muscular dystrophy"],"prefix":"10.1007","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8796-8123","authenticated-orcid":false,"given":"Peter P.","family":"Nghiem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe N.","family":"Kornegay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,7]]},"reference":[{"issue":"2","key":"1976_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/mus.20586","volume":"34","author":"A Aartsma-Rus","year":"2006","unstructured":"Aartsma-Rus A et al (2006) Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34(2):135\u2013144 (review)","journal-title":"Muscle Nerve"},{"issue":"12","key":"1976_CR2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.nmd.2016.09.024","volume":"26","author":"AR Acosta","year":"2016","unstructured":"Acosta AR et al (2016) Use of the six-minute walk test to characterize golden retriever muscular dystrophy. Neuromuscul Disord 26(12):865\u2013872","journal-title":"Neuromuscul Disord"},{"issue":"6410","key":"1976_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1126\/science.aau1549","volume":"362","author":"L Amoasii","year":"2018","unstructured":"Amoasii L et al (2018) Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science 362(6410):86\u201391","journal-title":"Science"},{"issue":"34","key":"1976_CR4","doi-asserted-by":"publisher","first-page":"13763","DOI":"10.1073\/pnas.1204638109","volume":"109","author":"Y Aoki","year":"2012","unstructured":"Aoki Y et al (2012) Bodywide skipping of exons 45\u201355 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci USA 109(34):13763\u201313768","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"1976_CR5","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1073\/pnas.1118847109","volume":"109","author":"WA Beltran","year":"2012","unstructured":"Beltran WA et al (2012) Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci USA 109(6):2132\u20132137","journal-title":"Proc Natl Acad Sci USA"},{"key":"1976_CR6","doi-asserted-by":"publisher","first-page":"16007","DOI":"10.1038\/ncomms16007","volume":"8","author":"NE Bengtsson","year":"2017","unstructured":"Bengtsson NE et al (2017) Corrigendum: muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun 8:16007","journal-title":"Nat Commun"},{"key":"1976_CR7","first-page":"193","volume":"25","author":"SM Birch","year":"2017","unstructured":"Birch SM et al (2017) A blinded, placebo-controlled systemic gene therapy efficacy study in the GRMD model of Duchenne muscular dystrophy. Mol Ther 25:193","journal-title":"Mol Ther"},{"issue":"4","key":"1976_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen CL et al (2015) The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 36(4):395\u2013402","journal-title":"Hum Mutat"},{"issue":"7","key":"1976_CR9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1089\/hum.2017.151","volume":"29","author":"AM Bradbury","year":"2018","unstructured":"Bradbury AM et al (2018) AAVrh10 gene therapy ameliorates central and peripheral nervous system disease in canine globoid cell leukodystrophy (Krabbe disease). Hum Gene Ther 29(7):785\u2013801","journal-title":"Hum Gene Ther"},{"issue":"4","key":"1976_CR10","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1073\/pnas.81.4.1189","volume":"81","author":"G Bulfield","year":"1984","unstructured":"Bulfield G et al (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 81(4):1189\u20131192","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"1976_CR11","doi-asserted-by":"publisher","first-page":"e0151800","DOI":"10.1371\/journal.pone.0151800","volume":"11","author":"MB Callan","year":"2016","unstructured":"Callan MB et al (2016) Successful phenotype improvement following gene therapy for severe hemophilia A in privately owned dogs. PLoS One 11(3):e0151800","journal-title":"PLoS One"},{"key":"1976_CR12","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1073\/pnas.93.8.3570","volume":"93","author":"N Deconinck","year":"1996","unstructured":"Deconinck N et al (1996) Functional protection of dystrophic mouse (mdx) muscles after adenovirus-mediated transfer of a dystrophin minigene. Proc Natl Acad Sci USA 93:3570\u20133574","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Pt 2","key":"1976_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1042\/bj20031311","volume":"379","author":"P Dowling","year":"2004","unstructured":"Dowling P et al (2004) Drastic reduction of sarcalumenin in Dp427 (dystrophin of 427 kDa)-deficient fibres indicates that abnormal calcium handling plays a key role in muscular dystrophy. Biochem J 379(Pt 2):479\u2013488","journal-title":"Biochem J"},{"issue":"1","key":"1976_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1089\/nat.2013.0451","volume":"24","author":"Y Echigoya","year":"2014","unstructured":"Echigoya Y, Yokota T (2014) Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides. Nucleic Acid Ther 24(1):57\u201368","journal-title":"Nucleic Acid Ther"},{"issue":"3","key":"1976_CR15","doi-asserted-by":"publisher","first-page":"e0120058","DOI":"10.1371\/journal.pone.0120058","volume":"10","author":"Y Echigoya","year":"2015","unstructured":"Echigoya Y et al (2015) In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy. PLoS One 10(3):e0120058","journal-title":"PLoS One"},{"issue":"16","key":"1976_CR16","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1073\/pnas.1613203114","volume":"114","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y et al (2017) Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA 114(16):4213\u20134218","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"1976_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.nmd.2013.10.005","volume":"24","author":"Z Fan","year":"2014","unstructured":"Fan Z et al (2014) Characteristics of magnetic resonance imaging biomarkers in a natural history study of golden retriever muscular dystrophy. Neuromuscul Disord 24(2):178\u2013191","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"1976_CR18","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/mt.2010.45","volume":"18","author":"S Fletcher","year":"2010","unstructured":"Fletcher S et al (2010) Dystrophin isoform induction in vivo by antisense-mediated alternative splicing. Mol Ther 18(6):1218\u20131223","journal-title":"Mol Ther"},{"key":"1976_CR19","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/hmg\/ddg141","volume":"12","author":"R Gilbert","year":"2003","unstructured":"Gilbert R et al (2003) Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus-encoding murine dystrophin. Hum Mol Genet 12:1287\u20131299","journal-title":"Hum Mol Genet"},{"key":"1976_CR20","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/mt.2008.28","volume":"16","author":"P Gregorevic","year":"2008","unstructured":"Gregorevic P et al (2008) Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Mol Ther 16:657\u2013664","journal-title":"Mol Ther"},{"issue":"3","key":"1976_CR21","first-page":"179","volume":"31","author":"T Grimm","year":"2012","unstructured":"Grimm T et al (2012) Risk assessment and genetic counseling in families with Duchenne muscular dystrophy. Acta Myol 31(3):179\u2013183","journal-title":"Acta Myol"},{"issue":"6","key":"1976_CR22","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP et al (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51(6):919\u2013928","journal-title":"Cell"},{"issue":"2","key":"1976_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/(SICI)1097-4598(199802)21:2<159::AID-MUS2>3.0.CO;2-A","volume":"21","author":"JM Howell","year":"1998","unstructured":"Howell JM et al (1998a) Direct dystrophin and reporter gene transfer into dog muscle in vivo. Muscle Nerve 21(2):159\u2013165","journal-title":"Muscle Nerve"},{"issue":"5","key":"1976_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1089\/hum.1998.9.5-629","volume":"9","author":"JM Howell","year":"1998","unstructured":"Howell JM et al (1998b) High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppression. Hum Gene Ther 9(5):629\u2013634","journal-title":"Hum Gene Ther"},{"issue":"9","key":"1976_CR25","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1038\/mt.2008.120","volume":"16","author":"N Jearawiriyapaisarn","year":"2008","unstructured":"Jearawiriyapaisarn N et al (2008) Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 16(9):1624\u20131629","journal-title":"Mol Ther"},{"key":"1976_CR26","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1128\/JVI.72.5.4212-4223.1998","volume":"72","author":"K Jooss","year":"1998","unstructured":"Jooss K et al (1998) Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 72:4212\u20134223","journal-title":"J Virol"},{"key":"1976_CR66","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0713","author":"H Komaki","year":"2018","unstructured":"Komaki H et al (2018) Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy. Sci Transl Med. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.aan0713","journal-title":"Sci Transl Med"},{"issue":"1","key":"1976_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13395-017-0124-z","volume":"7","author":"JN Kornegay","year":"2017","unstructured":"Kornegay JN (2017) The golden retriever model of Duchenne muscular dystrophy. Skelet Muscle 7(1):9. (review)","journal-title":"Skelet Muscle"},{"issue":"10","key":"1976_CR28","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/mus.880111008","volume":"11","author":"JN Kornegay","year":"1988","unstructured":"Kornegay JN et al (1988) Muscular dystrophy in a litter of golden retriever dogs. Muscle Nerve 11(10):1056\u20131064","journal-title":"Muscle Nerve"},{"issue":"8","key":"1976_CR29","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/mt.2010.94","volume":"18","author":"JN Kornegay","year":"2010","unstructured":"Kornegay JN et al (2010) Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther 18(8):1501\u20131508","journal-title":"Mol Ther"},{"issue":"1\u20132","key":"1976_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00335-011-9382-y","volume":"23","author":"JN Kornegay","year":"2012","unstructured":"Kornegay JN et al (2012) Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome 23(1\u20132):85\u2013108 (review)","journal-title":"Mamm Genome"},{"issue":"1","key":"1976_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/ilar\/ilu011","volume":"55","author":"JN Kornegay","year":"2014","unstructured":"Kornegay JN et al (2014) Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials. ILAR J 55(1):119\u2013149 (review)","journal-title":"ILAR J"},{"issue":"7491","key":"1976_CR32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nature11556","volume":"490","author":"SC Landis","year":"2012","unstructured":"Landis SC et al (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490(7491):187\u2013191","journal-title":"Nature"},{"key":"1976_CR33","doi-asserted-by":"publisher","first-page":"16105","DOI":"10.1038\/ncomms16105","volume":"8","author":"C Guiner Le","year":"2017","unstructured":"Le Guiner C et al (2017) Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun 8:16105","journal-title":"Nat Commun"},{"issue":"6271","key":"1976_CR34","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1126\/science.aad5725","volume":"351","author":"C Long","year":"2016","unstructured":"Long C et al (2016) Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351(6271):400\u2013403","journal-title":"Science"},{"issue":"8","key":"1976_CR35","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/nm897","volume":"9","author":"QL Lu","year":"2003","unstructured":"Lu QL et al (2003) Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9(8):1009\u20131014","journal-title":"Nat Med"},{"key":"1976_CR36","first-page":"CD003725","volume":"5","author":"E Matthews","year":"2016","unstructured":"Matthews E et al (2016) Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev 5:CD003725","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1976_CR37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","volume":"2","author":"AP Monaco","year":"1988","unstructured":"Monaco AP et al (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2(1):90\u201395","journal-title":"Genomics"},{"issue":"3","key":"1976_CR38","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF02717891","volume":"83","author":"MW Nachman","year":"2004","unstructured":"Nachman MW (2004) Haldane and the first estimates of the human mutation rate. J Genet 83(3):231\u2013233 (Erratum in: J Genet. 2008 Dec;87(3):317)","journal-title":"J Genet"},{"issue":"5","key":"1976_CR39","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/jth.13301","volume":"14","author":"TC Nichols","year":"2016","unstructured":"Nichols TC et al (2016) Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies. J Thromb Haemost 14(5):894\u2013905","journal-title":"J Thromb Haemost"},{"issue":"9","key":"1976_CR40","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1038\/mt.2013.111","volume":"21","author":"DG Ousterout","year":"2013","unstructured":"Ousterout DG et al (2013) Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Mol Ther 21(9):1718\u20131726 (Erratum in Mol Ther. 21(11):2130)","journal-title":"Mol Ther"},{"issue":"3","key":"1976_CR41","doi-asserted-by":"publisher","first-page":"B171","DOI":"10.1093\/gerona\/52A.3.B171","volume":"52","author":"GJ Patronek","year":"1997","unstructured":"Patronek GJ et al (1997) Comparative longevity of pet dogs and humans: implications for gerontology research. J Gerontol A Biol Sci Med Sci 52(3):B171\u2013B178","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1976_CR42","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/361647a0","volume":"361","author":"T Ragot","year":"1993","unstructured":"Ragot T et al (1993) Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 361:647\u2013650","journal-title":"Nature"},{"key":"1976_CR43","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1517\/21678707.2015.1088780","volume":"3","author":"J Ramos","year":"2015","unstructured":"Ramos J, Chamberlain JS (2015) Gene therapy for Duchenne muscular dystrophy. Expert Opin Orphan Drugs 3:1255\u20131266","journal-title":"Expert Opin Orphan Drugs"},{"issue":"5","key":"1976_CR44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0960-8966(99)00011-5","volume":"9","author":"SJ Schatzberg","year":"1999","unstructured":"Schatzberg SJ et al (1999) Molecular analysis of a spontaneous dystrophin \u2018knockout\u2019 dog. Neuromuscul Disord 9(5):289\u2013295","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"1976_CR45","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1007\/s11307-018-1174-2","volume":"20","author":"SM Schneider","year":"2018","unstructured":"Schneider SM et al (2018) Glucose metabolism as a pre-clinical biomarker for the golden retriever model of Duchenne muscular dystrophy. Mol Imaging Biol 20(5):780\u2013788","journal-title":"Mol Imaging Biol"},{"key":"1976_CR46","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1538\/expanim.52.93","volume":"52","author":"Y Shimatsu","year":"2003","unstructured":"Shimatsu Y et al (2003) Canine X-linked muscular dystrophy in Japan (CXMDJ). Exp Anim 52:93\u201397","journal-title":"Exp Anim"},{"key":"1976_CR47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-1-4939-7374-3_10","volume":"1687","author":"T Shimo","year":"2018","unstructured":"Shimo T et al (2018) Designing effective antisense oligonucleotides for exon skipping. Methods Mol Biol 1687:143\u2013155","journal-title":"Methods Mol Biol"},{"issue":"4912","key":"1976_CR48","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1126\/science.2662404","volume":"244","author":"P Sicinski","year":"1989","unstructured":"Sicinski P et al (1989) The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244(4912):1578\u20131580","journal-title":"Science"},{"issue":"Pt 17","key":"1976_CR49","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1242\/jeb.147058","volume":"220","author":"LU Sneddon","year":"2017","unstructured":"Sneddon LU et al (2017) Considering aspects of the 3Rs principles within experimental animal biology. J Exp Biol 220(Pt 17):3007\u20133016","journal-title":"J Exp Biol"},{"issue":"7631","key":"1976_CR50","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nature20565","volume":"540","author":"K Suzuki","year":"2016","unstructured":"Suzuki K et al (2016) In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration. Nature 540(7631):144\u2013149","journal-title":"Nature"},{"issue":"6271","key":"1976_CR51","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.aad5177","volume":"351","author":"M Tabebordbar","year":"2016","unstructured":"Tabebordbar M et al (2016) In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351(6271):407\u2013411","journal-title":"Science"},{"issue":"1","key":"1976_CR52","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1089\/hum.2006.093","volume":"18","author":"Z Wang","year":"2007","unstructured":"Wang Z et al (2007a) Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther 18(1):18\u201326","journal-title":"Hum Gene Ther"},{"issue":"6","key":"1976_CR53","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/sj.mt.6300161","volume":"15","author":"Z Wang","year":"2007","unstructured":"Wang Z et al (2007b) Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 15(6):1160\u20131166","journal-title":"Mol Ther"},{"issue":"2","key":"1976_CR54","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/ilar.50.2.187","volume":"50","author":"Z Wang","year":"2009","unstructured":"Wang Z et al Chamberlain JS, Tapscott SJ, Storb R (2009) Gene therapy in large animal models of muscular dystrophy. ILAR J 50(2):187\u2013198. Review","journal-title":"ILAR J"},{"issue":"2","key":"1976_CR55","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3233\/JND-140067","volume":"2","author":"R Willmann","year":"2015","unstructured":"Willmann R et al (2015) Best practices and standard protocols as a tool to enhance translation for neuromuscular disorders. J Neuromuscul Dis 2(2):113\u2013117","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"1976_CR56","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.gene.2013.03.137","volume":"525","author":"T Wirth","year":"2013","unstructured":"Wirth T et al (2013) History of gene therapy. Gene 525(2):162\u2013169","journal-title":"Gene"},{"issue":"5","key":"1976_CR57","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/mt.2009.38","volume":"17","author":"B Wu","year":"2009","unstructured":"Wu B et al (2009) Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther 17(5):864\u2013871","journal-title":"Mol Ther"},{"key":"1976_CR58","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1128\/JVI.70.11.8098-8108.1996","volume":"70","author":"X Xiao","year":"1996","unstructured":"Xiao X et al (1996) Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 70:8098\u20138108","journal-title":"J Virol"},{"issue":"3","key":"1976_CR59","first-page":"179","volume":"26","author":"T Yokota","year":"2007","unstructured":"Yokota T et al (2007) Optimizing exon skipping therapies for DMD. Acta Myol 26(3):179\u2013184. Review","journal-title":"Acta Myol"},{"issue":"6","key":"1976_CR60","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/ana.21627","volume":"65","author":"T Yokota","year":"2009","unstructured":"Yokota T et al (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65(6):667\u2013676","journal-title":"Ann Neurol"},{"issue":"5","key":"1976_CR61","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1089\/nat.2012.0368","volume":"22","author":"T Yokota","year":"2012","unstructured":"Yokota T et al (2012) Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther 22(5):306\u2013315","journal-title":"Nucleic Acid Ther"},{"issue":"20","key":"1976_CR62","doi-asserted-by":"publisher","first-page":"5880","DOI":"10.1093\/hmg\/ddv310","volume":"24","author":"Y Yue","year":"2015","unstructured":"Yue Y et al (2015) Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. Hum Mol Genet 24(20):5880\u20135890","journal-title":"Hum Mol Genet"},{"issue":"4","key":"1976_CR63","doi-asserted-by":"publisher","first-page":"e1602814","DOI":"10.1126\/sciadv.1602814","volume":"3","author":"Y Zhang","year":"2017","unstructured":"Zhang Y et al (2017) CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice. Sci Adv 3(4):e1602814","journal-title":"Sci Adv"},{"key":"1976_CR64","unstructured":"https:\/\/www.fda.gov\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/ucm581222.htm\n                    \n                  . Accessed Jan 2019"},{"key":"1976_CR65","unstructured":"https:\/\/ghr.nlm.nih.gov\/primer\/therapy\/genetherapy\n                    \n                  . Accessed Jan 2019"}],"updated-by":[{"DOI":"10.1007\/s00439-019-01982-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T00:00:00Z","timestamp":1550534400000}}],"container-title":["Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00439-019-01976-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00439-019-01976-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00439-019-01976-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T19:07:52Z","timestamp":1581016072000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00439-019-01976-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,7]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["1976"],"URL":"https:\/\/doi.org\/10.1007\/s00439-019-01976-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00439-019-01982-1","asserted-by":"object"}]},"ISSN":["0340-6717","1432-1203"],"issn-type":[{"value":"0340-6717","type":"print"},{"value":"1432-1203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,7]]},"assertion":[{"value":"4 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors would like to correct the following information concerning Conflict of Interest.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Nghiem is a paid consultant for Agada Biosciences. Dr. Kornegay does not have any conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}